Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of Topiramate as an add-on Therapy in the Treatment of Epilepsy Patients With Lennox-Gastaut Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Body weight of at least 25 pounds~* diagnosis of Lennox-Gastaut syndrome and an electroencephalogram (EEG) with an abnormal pulsation pattern~* atypical absence seizures and drop attacks (i.e., tonic-atonic seizures) among other seizure types that could include tonic-clonic, myoclonic, and minor-motor~* at least 60 seizures during the month before baseline~* must be maintained on 1 or 2 antiepileptic drugs~* females must not have had their first menstrual period, or are physically incapable of child bearing, or if of child bearing potential, sexually abstinent, or using adequate contraceptive measures, and have a negative pregnancy test before study entry.~Exclusion Criteria:~* Patients whose seizures are due to a progressive disease (for example, active infection, cancer or metabolic disturbance)~* have a significant recent history (within 2 years) of medical diseases (respiratory, heart, gastrointestinal, blood diseases, rheumatic fever or cancer)~* history of alcohol or drug abuse.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 30 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).